Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
FBXW7 Targets mTOR for Degradation and Cooperates with PTEN in Tumor Suppression
Jian-Hua Mao,1*
Il-Jin Kim,1*
Di Wu,1
Joan Climent,1
Hio Chung Kang,1
Reyno DelRosario,1
Allan Balmain1,2
Abstract:
The enzyme mTOR (mammalian target of rapamycin) is a major targetfor therapeutic intervention to treat many human diseases, includingcancer, but very little is known about the processes that controllevels of mTOR protein. Here, we show that mTOR is targetedfor ubiquitination and consequent degradation by binding tothe tumor suppressor protein FBXW7. Human breast cancer celllines and primary tumors showed a reciprocal relation betweenloss of FBXW7 and deletion or mutation of PTEN (phosphataseand tensin homolog), which also activates mTOR. Tumor cell linesharboring deletions or mutations in FBXW7 are particularly sensitiveto rapamycin treatment, which suggests that loss of FBXW7 maybe a biomarker for human cancers susceptible to treatment withinhibitors of the mTOR pathway.
1 Cancer Research Institute, University of California at San Francisco, 2340 Sutter Street, San Francisco, CA 94143, USA. 2 Department of Biochemistry and Biophysics, University of California at San Francisco, San Francisco, CA 94143, USA.
* These authors contributed equally to this work.
To whom correspondence should be addressed. E-mail: abalmain{at}cc.ucsf.edu
The editors suggest the following Related Resources on Science sites:
In Science Signaling
EDITORS' CHOICE
Stella M. Hurtley (16 September 2008) Sci. Signal.1 (37), ec325.
[DOI: 10.1126/scisignal.137ec325] |Abstract »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Role of Ubiquitin Ligases and the Proteasome in Oncogenesis: Novel Targets for Anticancer Therapies.
L. N. Micel, J. J. Tentler, P. G. Smith, and G. S. Eckhardt (2013)
J. Clin. Oncol.
31, 1231-1238
|Abstract »|Full Text »|PDF »
Transforming Growth Factor {beta} Integrates Smad 3 to Mechanistic Target of Rapamycin Complexes to Arrest Deptor Abundance for Glomerular Mesangial Cell Hypertrophy.
F. Das, N. Ghosh-Choudhury, A. Bera, N. Dey, H. E. Abboud, B. S. Kasinath, and G. G. Choudhury (2013)
J. Biol. Chem.
288, 7756-7768
|Abstract »|Full Text »|PDF »
Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models.
J. M. Spoerke, C. O'Brien, L. Huw, H. Koeppen, J. Fridlyand, R. K. Brachmann, P. M. Haverty, A. Pandita, S. Mohan, D. Sampath, et al. (2012)
Clin. Cancer Res.
18, 6771-6783
|Abstract »|Full Text »|PDF »
Human Molecular Genetic and Functional Studies Identify TRIM63, Encoding Muscle RING Finger Protein 1, as a Novel Gene for Human Hypertrophic Cardiomyopathy.
S. N. Chen, G. Czernuszewicz, Y. Tan, R. Lombardi, J. Jin, J. T. Willerson, and A. J. Marian (2012)
Circ. Res.
111, 907-919
|Abstract »|Full Text »|PDF »
DEPTOR ubiquitination and destruction by SCF{beta}-TrCP.
Z. Wang, J. Zhong, D. Gao, H. Inuzuka, P. Liu, and W. Wei (2012)
Am J Physiol Endocrinol Metab
303, E163-E169
|Abstract »|Full Text »|PDF »
Pten Regulates Aurora-A and Cooperates with Fbxw7 in Modulating Radiation-Induced Tumor Development.
Y.-W. Kwon, I.-J. Kim, D. Wu, J. Lu, W. A. Stock Jr, Y. Liu, Y. Huang, H. C. Kang, R. DelRosario, K.-Y. Jen, et al. (2012)
Mol. Cancer Res.
10, 834-844
|Abstract »|Full Text »|PDF »
Triggering Fbw7-Mediated Proteasomal Degradation of c-Myc by Oridonin Induces Cell Growth Inhibition and Apoptosis.
H.-L. Huang, H.-Y. Weng, L.-Q. Wang, C.-H. Yu, Q.-J. Huang, P.-P. Zhao, J.-Z. Wen, H. Zhou, and L.-H. Qu (2012)
Mol. Cancer Ther.
11, 1155-1165
|Abstract »|Full Text »|PDF »
ROR{alpha} Suppresses Breast Tumor Invasion by Inducing SEMA3F Expression.
G. Xiong, C. Wang, B. M. Evers, B. P. Zhou, and R. Xu (2012)
Cancer Res.
72, 1728-1739
|Abstract »|Full Text »|PDF »
Sequential mutations in Notch1, Fbxw7, and Tp53 in radiation-induced mouse thymic lymphomas.
K.-Y. Jen, I. Y. Song, K. L. Banta, D. Wu, J.-H. Mao, and A. Balmain (2012)
Blood
119, 805-809
|Abstract »|Full Text »|PDF »
Paracrine Signaling Through MYCN Enhances Tumor-Vascular Interactions in Neuroblastoma.
Y. H. Chanthery, W. C. Gustafson, M. Itsara, A. Persson, C. S. Hackett, M. Grimmer, E. Charron, S. Yakovenko, G. Kim, K. K. Matthay, et al. (2012)
Science Translational Medicine
4, 115ra3
|Abstract »|Full Text »|PDF »
Control of mTORC1 signaling by the Opitz syndrome protein MID1.
E. Liu, C. A. Knutzen, S. Krauss, S. Schweiger, and G. G. Chiang (2011)
PNAS
108, 8680-8685
|Abstract »|Full Text »|PDF »
Fbxw7-dependent Degradation of Notch Is Required for Control of "Stemness" and Neuronal-Glial Differentiation in Neural Stem Cells.
A. Matsumoto, I. Onoyama, T. Sunabori, R. Kageyama, H. Okano, and K. I. Nakayama (2011)
J. Biol. Chem.
286, 13754-13764
|Abstract »|Full Text »|PDF »
mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets.
Ex vivo maintenance of hematopoietic stem cells by quiescence induction through Fbxw7{alpha} overexpression.
H. Iriuchishima, K. Takubo, S. Matsuoka, I. Onoyama, K. I. Nakayama, Y. Nojima, and T. Suda (2011)
Blood
117, 2373-2377
|Abstract »|Full Text »|PDF »
FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation.
R. Babaei-Jadidi, N. Li, A. Saadeddin, B. Spencer-Dene, A. Jandke, B. Muhammad, E. E. Ibrahim, R. Muraleedharan, M. Abuzinadah, H. Davis, et al. (2011)
J. Exp. Med.
208, 295-312
|Abstract »|Full Text »|PDF »
Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted Therapies.
Notch-dependent expression of the archipelago ubiquitin ligase subunit in the Drosophila eye.
S. C. Nicholson, B. N. Nicolay, M. V. Frolov, and K. H. Moberg (2011)
Development
138, 251-260
|Abstract »|Full Text »|PDF »
mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy.
X. Song, Y. Kusakari, C.-Y. Xiao, S. D. Kinsella, M. A. Rosenberg, M. Scherrer-Crosbie, K. Hara, A. Rosenzweig, and T. Matsui (2010)
Am J Physiol Cell Physiol
299, C1256-C1266
|Abstract »|Full Text »|PDF »
MicroRNA-223 Regulates Cyclin E Activity by Modulating Expression of F-box and WD-40 Domain Protein 7.
Y. Xu, T. Sengupta, L. Kukreja, and A. C. Minella (2010)
J. Biol. Chem.
285, 34439-34446
|Abstract »|Full Text »|PDF »
Monitoring the Outside: Cell Wall-Sensing Mechanisms.
C. Ringli (2010)
Plant Physiology
153, 1445-1452
|Full Text »|PDF »
The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy.
T. A. Soucy, L. R. Dick, P. G. Smith, M. A. Milhollen, and J. E. Brownell (2010)
Genes & Cancer
1, 708-716
|Abstract »|Full Text »|PDF »
The Fbw7/Human CDC4 Tumor Suppressor Targets Proproliferative Factor KLF5 for Ubiquitination and Degradation through Multiple Phosphodegron Motifs.
N. Liu, H. Li, S. Li, M. Shen, N. Xiao, Y. Chen, Y. Wang, W. Wang, R. Wang, Q. Wang, et al. (2010)
J. Biol. Chem.
285, 18858-18867
|Abstract »|Full Text »|PDF »
The Fbw7 Tumor Suppressor Targets KLF5 for Ubiquitin-Mediated Degradation and Suppresses Breast Cell Proliferation.
D. Zhao, H.-Q. Zheng, Z. Zhou, and C. Chen (2010)
Cancer Res.
70, 4728-4738
|Abstract »|Full Text »|PDF »
Validation of SAG/RBX2/ROC2 E3 Ubiquitin Ligase as an Anticancer and Radiosensitizing Target.
L. Jia, J. Yang, X. Hao, M. Zheng, H. He, X. Xiong, L. Xu, and Y. Sun (2010)
Clin. Cancer Res.
16, 814-824
|Abstract »|Full Text »|PDF »
Perifosine Inhibits Mammalian Target of Rapamycin Signaling through Facilitating Degradation of Major Components in the mTOR Axis and Induces Autophagy.
L. Fu, Y.-A. Kim, X. Wang, X. Wu, P. Yue, S. Lonial, F. R. Khuri, and S.-Y. Sun (2009)
Cancer Res.
69, 8967-8976
|Abstract »|Full Text »|PDF »
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
W. Fiskus, Y. Wang, A. Sreekumar, K. M. Buckley, H. Shi, A. Jillella, C. Ustun, R. Rao, P. Fernandez, J. Chen, et al. (2009)
Blood
114, 2733-2743
|Abstract »|Full Text »|PDF »
Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer.
D. Sarker, A. H.M. Reid, T. A. Yap, and J. S. de Bono (2009)
Clin. Cancer Res.
15, 4799-4805
|Abstract »|Full Text »|PDF »
Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer.
T. A. Soucy, P. G. Smith, and M. Rolfe (2009)
Clin. Cancer Res.
15, 3912-3916
|Abstract »|Full Text »|PDF »
A Phosphorylation Cascade Controls the Degradation of Active SREBP1.
M. T. Bengoechea-Alonso and J. Ericsson (2009)
J. Biol. Chem.
284, 5885-5895
|Abstract »|Full Text »|PDF »